Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dengzhan Shengmai Capsule in Amnestic Mild Cognitive Impairment
ChiCTR-IPR-17011556Phase 4Recruiting
- Sponsor
- Beijing Aging Brain Rejuvenation Initiative
- Start
- Jun 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in amnestic mild cognitive impairment (MCI) comparing Dengzhan Shengmai Capsule group with Placebo control group (2 arms). Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), Auditory Verbal Learning Test (AVLT) and 5 more. Started Jun 2017; status: recruiting.
02
Drugs
Dengzhan Shengmai
03
Conditions
amnestic mild cognitive impairment (MCI)
Beyond the preview
Go deeper on ChiCTR-IPR-17011556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011556.